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Abstract
Disease phenotyping algorithms process observational clinical data to identify
patients with specific diseases. Supervised phenotyping methods require significant
quantities of expert-labeled data, while unsupervised methods may learn non-
disease phenotypes. To address these limitations, we propose the Semi-Supervised
Mixed Membership Model (SS3M) – a probabilistic graphical model for learning
disease phenotypes from clinical data with relatively few labels. We show SS3M
can learn interpretable, disease-specific phenotypes which capture the clinical
characteristics of the diseases specified by the labels provided.
1 Introduction
Phenotypes are powerful tools for working with observational clinical data in the absence of reliable
disease labels [1]. Disease-specific phentoypes allow researchers to sift through large-scale clinical
data stores to identify patients with evidence of specific clinical conditions. By answering the question
of who has what disease, phenotypes power essential tasks such as cohort selection, trial recruitment
and clinical outcome prediction [1–4].
Traditionally, phenotypes were developed by groups of clinical experts who painstakingly hand-
tuned rule-based algorithms. The limited scalability of this approach has led to the development of
automated methods for learning phenotypes directly from clinical data. Many studies in this vein
utilize supervised machine learning methods to build phenotyping algorithms [5, 6]. Though this
approach avoids laborious expert knowledge engineering, it requires significant amounts of labeled
clinical data generated by manual chart review.
To avoid costly, expert-generated disease labels, many authors have utilized unsupervised methods
to cluster patients according to underlying patterns in their clincal data [7–11]. In this setting,
such patterns play the role of phenotypes. Unsupervised phenotyping methods often learn multiple
phenotypes simultaneouly, which may confer evidence of specific diseases. However, such phenotypes
generally are not guaranteed to represent single disease concepts. This complicates their evaluation
and use in downstream tasks.
In this paper we propose the Semi-Supervised Mixed Membership Model (SS3M), a probabilistic
graphical model which utilizes relatively few disease labels to learn multiple disease-specific pheno-
types from observational clinical data. SS3M addresses the limitations of supervised phenotyping
by reducing the amount of labeled data needed to learn disease phenotypes; patients do not need
to have labels for all diseases. SS3M also addresses the limitations of unsupervised phenotyping
by associating disease labels with the phenotypes to be learned; a label specifies which disease a
phenotype is meant to represent. This simplifies the evaluation of SS3M phenotypes.
Machine Learning for Health (ML4H) Workshop at NeurIPS 2018.
ar
X
iv
:1
81
2.
03
22
2v
2 
 [c
s.L
G]
  2
6 M
ar 
20
19
Our overall goal is to utilize SS3M in an active learning framework, where we may request small
batches of labels from clinical experts as needed to learn a phenotype for a given disease. In the
present work, we aim to evaluate SS3M’s capacity for learning disease-specific phenotypes by
utilizing readily available ICD9 diagnosis codes as our labels. We consider this phase in our work a
crucial step towards obtaining a reliable semi-supervised model.
2 Semi-Supervised Mixed Memberships Models
SS3M is closely related to the popular topic model Latent Dirichlet Allocation (LDA) [12], and its
multi-modal [13] and supervised [14] extensions. We detail the generative process for SS3M and
provide a graphical model in the appendix.
Inference We implement a Gibbs sampler to sample latent variables from SS3M’s posterior distribu-
tion. Conjugacy gives us the complete conditional distributions for the patient-phenotype distributions,
θd, and phenotype-token distributions, φsp, in closed form. The complete conditionals for phenotype
assignments, zsdn, and phenotype activations, Adp, are easily normalized. We use Hamiltonian
Monte Carlo to sample from the complete conditionals of Bp and B∗ [15]. Setting the path length
L = 25 and step size  = 0.01 yielded stable trajectories with high acceptance rates in preliminary
experiments.
3 Experiments
3.1 Dataset
We train all our models using clinical data extracted from the Medical Information Mart for Intensive
Care version III (MIMIC-III) [16]. Our dataset is restricted to the first hospital admission of 46,520
neonatal and adult patients. Clinical notes, labs, and medications comprise corpora of clinical
observations. The 50 most common ICD9 diagnosis codes form our label set. Tokenized clinical
observation corpora were preprocessed to remove stopwords as well as low- and high-frequency
tokens. The final preprocessed corpora and labels were then split into training and test sets containing
data for 80% and 20% of patients respectively.
3.2 SS3M
We train SS3M to learn P = 70 phenotypes; 50 labeled phenotypes (one for each ICD9 diagnosis
code label) and 20 unlabeled phenotypes. In preliminary experiments, we found the addition of
unlabeled phenotypes improved the overall interpretability of their labeled counterparts.
For a given patient, the model may treat the absence of a label in two ways. In the first, a missing
label indicates that the label’s activation, Adp, should be set to 0. In the second, an absent label
indicates the corresponding activation should be estimated. This latter case is meant to model the
uncertainty associated with assignment of diagnosis codes in clinical settings. We train seperate
models to explore both cases.
During inference, we have the option to sample the Bp and B∗ or hold them fixed. Preliminary
experiments suggest holding these variables fixed results in more interpretable labeled phenotypes.
We explore both cases initializing the Bp and B∗ with draws from Gamma distributions with shape
and scale parameters (10.0, 1.0) and (0.01, 1.0) respectively.
In all experiments we set α = 0.1 and γs = (.01, ..., .01), and sampled latent variables for 200
iterations.
3.3 Quantitative evaluation
In all cases involving mixed membership models, global latent variables are learned on the training
set. Trained global variables are then loaded into models exposed to patient data in the test set.
Label prediction For SS3M, we estimate each test patient’s posterior likelihood for each disease
label. We evaluate against logistic regression (LR) and naive Bayes (NB) models trained with raw
tokens or patient-phenotype distributions learned with either of two mixed membership models. The
first of these is the multi-channel mixed membership model (MC3M) – an unsupervised model similar
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in structure to SS3M but with a simple Dirichlet prior on the patient-phenotype distributions, θd [13].
The second is SS3M trained without labels. This model is effectively MC3M with a structured prior
(MC3M-SP) on the θd.
Log-likelihood We report the maximum complete data log-likelihoods observed during training of
each of our three mixed membership models: SS3M, MC3M, and MC3M-SP.
3.4 Qualitative evaluation
Here we leverage the judgement of a clinical expert to asses the quality of SS3M phenotypes relative
to MC3M phenotypes. In particluar, we aim to evaluate the coherence, granularity, and label quality
of learned phenotypes. We asked our clinical expert to complete the following tasks, which were
inspired by the expert evaluations detailed in Pivovarov et al. [13]
Coherence A coherent phenotype was defined as a phenotype containing observations typical of a
single disease while omitting observations atypical of said disease. The clinical expert was asked to
rate the coherence of individual phenotypes using a five-point Likert scale, with 1 and 5 signifying
low and and high coherence respectively.
Granularity We defined three categories of phenotype granularity: (1) non-disease, (2) mixture of
diseases, (3) single disease. We asked our expert to assign each phenotype to one of these categories.
Label quality We asked our clinical expert to generate a label for each phenotype. If no such label
came to mind, the expert was asked to omit this step. If the phenotype in question was learned using
SS3M, the expert was asked if their label was equivalent to the phenotype’s true label. In addition, the
expert was asked to specify how well the true label matched its learned phenotype using a five-point
Likert scale with 1 indicating no match and 5 a perfect match.
The phenotypes for our qualitative evaluations were learned using SS3M and MC3M models with
P = 70. The 50 labeled SS3M phenotypes and 50 randomly chosen MC3M phenotypes were shuffled
together. During the evaluation, a single phenotype was drawn and shown to our expert who then
completed the tasks above. This was repeated until all 100 phenotypes had been evaluated.
4 Results
Our clinical expert judged SS3M phenotypes to have higher coherence and granularity relative to
MC3M phenotypes. Though less than a quarter of the expert’s labels were found to match the true
labels for SS3M phenotypes, nearly half (48%) of these phenotypes were found to be good matches
for their true labels (Likert score ≥ 3). A summary of the results from our qualitative evaluation is
presented in Table 1. A sample of phenotypes judged to match both expert and true labels are shown
in Figure 1.
Nearly all multilabel classification baselines displayed superior performance relative to SS3M in
micro and macro averaged AUROC and AUPRC. Overall, logistic regression trained on raw tokens
displayed the best performance. Notably, among SS3M models, the simplest model holding missing
label activations fixed (fix A0) and fixing Bp and B∗ (fix B/B∗) was best in micro and macro
averaged AUROC. Meanwhile, the SS3M model with best micro and macro averaged AUPRC had
fixed missing activations and sampled Bp and B∗ (smpl B/B∗).
The overall best log-likelihood was obtained with our most flexible mixed membership model: SS3M
with sampled activations and sampled Bp and B∗. A summary of the results from our quantitative
evaluation is presented in Table 2
Table 1: Qualitative Evaluation Summary
Coherence Granularity True label matches phen.? True label matches expert’s?
1 2 3 4 5 1 2 3 1 2 3 4 5 Y N
SS3M 20% 8% 14% 36% 22% 24% 32% 44% 36% 16% 12% 22% 14% 26% 74%
MC3M 18% 28% 32% 20% 2% 42% 42% 16% – – – – – – –
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Figure 1: Sample of SS3M phenotypes with their true labels (ICD9 diagnosis codes), expert generated
labels, and qualitative evaluation results. Red tokens (top row): words from clinical notes. Green
tokens (middle row): clinical labs. Blue tokens (bottom row): medications. A token’s size represents
its probability relative to other tokens under the phenotype.
Table 2: Quantitative Evaluation Summary
SS3M MC3M-SP MC3M Raw Tokens
smpl A0 smpl A0 fix A0 fix A0 LR NB LR NB LR NBsmpl B/B∗ fix B/B∗ smpl B/B∗ fix B/B∗
AUROC micro 0.639 0.653 0.719 0.720 0.865 0.805 0.837 0.826 0.884 0.803macro 0.595 0.647 0.695 0.714 0.810 0.763 0.779 0.778 0.840 0.780
AUPRC micro 0.187 0.156 0.299 0.249 0.427 0.283 0.353 0.308 0.527 0.309macro 0.162 0.187 0.252 0.245 0.277 0.215 0.232 0.229 0.426 0.236
Log-likelihood −7.075× 108 −7.395× 108 −8.457× 108 −8.420× 108 −7.389× 108 −9.623× 108 –
5 Discussion
SS3M is a model constructed for learning disease phenotypes from observational clinical data in a
semi-supervised or active learning setting. As a preliminary step toward this goal, we have exposed
the model to MIMIC-III clinical data and derived phenotype labels from common ICD9 diagnosis
codes. In quantitative evaluations, SS3M was generally outperformed by baselines in predicting
disease labels on held out patient data. Meanwhile, in qualitative evaluations conducted by a clinical
expert, SS3M phenotypes were judged to be more coherent, and more granular than phenotypes
learned with a related unsupervised model. Moreover, SS3M phenotypes were often found to capture
the clinical characteristics of the clinical entities specified by their associated labels. These results
suggest that despite its weak performance on label prediction, SS3M does indeed appear capable of
learning interpretable, disease-specific phenotypes from clinical data.
SS3M’s weak predictive performance warrants some scrutiny. Suboptimal setting of the model’s fixed
parameters may be to blame. Indeed, in this work we did little to tune the model’s hyperparameters
or the total number of phenotypes to be learned. Exploring various settings of these fixed parameters
is likely to produce a model with improved predictive performance on held-out test data. It is also
possible that our choice of labels is hindering SS3M’s performance. ICD9 codes are notoriously
noisy proxies for ground-truth diagnosis. This leaves open the possibility that SS3M may actually be
generating correct labels for held-out patients who simply lack the appropriate labels for their true
underlying clinical conditions. We may better explore this possibility by incorporating SS3M into an
active learning framework where high-fidelity labels may be requested as needed from a clinician.
6 Conclusion
SS3M learns disease-specific phenotypes from labeled clinical data. Future work will explore
alternative parameterizations to optimize the model’s performance on multi-label prediction and
utilize higher fidelity label sets. The positive qualitative assessment of SS3M phenotypes encourages
us to continue developing SS3M for use in truly semi-supervised or active learning settings.
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Appendix
The generative process for SS3M is detailed below. The corresponding graphical models appears in
Figure 2
1. For each phenotype p ∈ {1, ..., P} and data source s ∈ {1, ..., S} draw a phenotype-token
distribution φsp ∼ Dir(γs).
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2. For each phenotype p ∈ {1, ..., P} draw Bp ∼ Gamma(β0, β1).
3. Draw B∗ ∼ Gamma(β∗0 , β∗1).
4. For each patient d ∈ {1, ..., D}:
(a) For each phenotype p ∈ {1, ..., P} draw phenotype activations Adp ∼ Bern(α)
(b) Draw a patient-phenotype distribution θd ∼ Dir(Ad,: B + (1−Ad,:)B∗)
(c) For each data source s ∈ {1, ..., S} and observation nsdn ∈ {1, ..., Nsd}
i. Draw a phenotype assignment zsdn ∼ Cat(θd)
ii. Draw an observed token wsdn ∼ Cat(φszsdn)
In steps 2, 3 and 4(a) we introduce patient-level binary phenotype activations Adp and global latent
variables Bp and B∗ which interact to parameterize the Dirichlet prior on each θd in step 4(b). For
patient d, if activation Adp = 1 then the pth parameter to the Dirichlet prior on θd is set to Bp;
otherwise, it is set to B∗.
Activations may be estimated, or they may be held fixed in accordance with a set of binary labels
reflecting the presence (1) or absence (0) of specific diseases. In this latter case, the presence of a
disease label corresponding to phenotype p for patient d would set Adp = 1 during inference. This
constrains the model to use Bp in the prior to θ′d instead of B
∗. The goal of introducing this structure
is to encourage the model to learn values for the Bp which push the θd to place most of their mass
over phenotypes with positive activations. Thus, by linking activations to labels, a patient’s data is
driven toward informing inference of phenotypes that capture the distinct clinical meanings associated
their labels.
Figure 2: Graphical model for SS3M
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